Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Daily Stock Ratings & Price Targets - Hong Kong
Analyst Performance
Any
Analyst Rating
Any
Upside / Downside
Any
Action
Any
Market Cap
Any
Analyst & Firm | Company | Price | Rating & Price Target | Upside / Downside | Success Rate | Average Return | Action | Date | Article |
|---|---|---|---|---|---|---|---|---|---|
 | Innovent Biologics | BUY HK$66.5 | ― | -18.00% | Assigned | Morgan Stanley Reiterates Overweight Rating on Innovent Biologics Inc. (1801:HK) (IVBXF)Morgan Stanley analyst Sean Wu reiterated an Overweight rating and HK$66.50 price target on Innovent Biologics Inc. (1801:HK) (OTC: IVBXF). | |||
| Cathay Pacific Airways | HOLD HK$8.1 | ― | -7.40% | Reiterated | Morgan Stanley Reiterates Equalweight Rating on Cathay Pacific Airways Ltd. (293:HK) (CPCAY)Morgan Stanley analyst Qianlei Fan reiterated an Equalweight rating and HK$8.10 price target on Cathay Pacific Airways Ltd. (293:HK) (OTC: CPCAY). | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD HK$1.4 | ― | 10.30% | Reiterated | ||||
Gareth LeungMorgan Stanley Not Ranked | NagaCorp | HOLD HK$3.25→HK$2.75 | ― | ― | Reiterated | NagaCorp: Hold Rating Amid Cautious Optimism and Persistent Challenges | |||
| Tencent Holdings Limited | BUY HK$570 | ― | -8.20% | Reiterated | Morgan Stanley Reiterates Overweight Rating on Tencent Holdings (700:HK) (TCEHY)Morgan Stanley analyst Gary Yu reiterated an Overweight rating and HK$570.00 price target on Tencent Holdings (700:HK) (OTC: TCEHY). | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY HK$69→HK$73 | ― | 6.10% | Reiterated | ||||
| Hansoh Pharmaceutical Group Company Limited | BUY HK$25.24 | ― | -2.70% | Reiterated | Hansoh Pharmaceutical Group: Strategic Positioning and Growth Prospects Drive Buy Rating | |||
GCL-Poly Energy Holdings | BUY HK$1.8→HK$1.3 | ― | -1.30% | Reiterated | GCL-Poly Energy Holdings: Leveraging Advanced Technology for Cost Reduction and Market Growth Amidst Price Pressures | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL HK$6→HK$2 | ― | 9.20% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY HK$6.5 | ― | 8.50% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY HK$45.5 | ― | 8.50% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY HK$6.1 | ― | 8.50% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD HK$4.5 | ― | 8.50% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD HK$5.95 | ― | 8.50% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD HK$4.8 | ― | 8.50% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY HK$4.25 | ― | 8.50% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY HK$4.2 | ― | 8.50% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD HK$2.65 | ― | 8.50% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL HK$2.01 | ― | 11.80% | Reiterated | ||||
| Akeso, Inc. | BUY HK$65 | ― | -14.70% | Reiterated | Bernstein Keeps Their Buy Rating on Akeso, Inc. (9926) | |||
| Innovent Biologics | BUY HK$47 | ― | -14.70% | Reiterated | Analysts' Opinions Are Mixed on These Healthcare Stocks: Outset Medical (NASDAQ: OM), Arvinas Holding Company (NASDAQ: ARVN) and Innovent Biologics (Other OTC: IVBXF) | |||
Phyllis WangUBS Not Ranked | Zoomlion Heavy Industry Science & Technology Co | HOLD HK$6.2→HK$6.1 | ― | ― | Reiterated | Zoomlion Heavy Industry Science #x26; Tech (H-Shares) (1157:HK) (ZLIOF) PT Lowered to HK$6.10 at UBSUBS analyst Phyllis Wang lowered the price target on Zoomlion Heavy Industry Science Tech (H-Shares) (1157:HK) (OTC: ZLIOF) to HK$6.10 (from HK$6.20) while maintaining a Neutral rating. | |||
| Hansoh Pharmaceutical Group Company Limited | BUY HK$24 | ― | -18.00% | Reiterated | Morgan Stanley Reiterates Overweight Rating on Hansoh Pharma (3692:HK) (HNSPF)Morgan Stanley analyst Sean Wu reiterated an Overweight rating and HK$24.00 price target on Hansoh Pharma (3692:HK) (OTC: HNSPF). | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD HK$14.9→HK$16.9 | ― | 24.50% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD HK$1.85→HK$2 | ― | 42.20% | Reiterated |
Rows:
